The American Journal of Bioethics · 2016 · 53 citations · 66 references
Public HealthPharmacologyPublic Health EthicsMedical EthicsResearch EthicsSubstance Use DisordersClinical Trial EthicsControlled Substance EthicsControlled SubstancesControlled Substances ClassificationSubstance Abuse PreventionBarriersControlled Substances InvestigationsEthical Informed ConsentEvidentiary Basis ReviewIllicit Drug PolicyInformed ConsentResearch Agenda SettingUndue Inducement
We examine the ethical, social, and regulatory barriers that may hinder research on therapeutic potential of certain controversial controlled substances like marijuana, heroin, or ketamine. Hazards for individuals and society and potential adverse effects on communities may be good reasons for limiting access and justify careful monitoring of these substances. Overly strict regulations, fear of legal consequences, stigma associated with abuse and populations using illicit drugs, and lack of funding may, however, limit research on their considerable therapeutic potential. We review the surprisingly sparse literature and address the particular ethical concerns pertinent to research with illicit and addictive substances, such as undue inducement, informed consent, therapeutic misconception, and risk to participants, researchers, and institutions. We consider the perspectives of key research stakeholders and explore whether they may be infected with bias. We conclude by proposing an empirical research agenda to provide an evidentiary basis for ethical reasoning.
66
Daniel Kahneman, Amos Tversky · American Psychologist · 1984 · 6.5K citations
Cochrane Database of Systematic Reviews
Progress in Neurology and Psychiatry · 2011 · 4.7K citations · Full text
The new Jim Crow: mass incarceration in the age of colorblindness
Choice Reviews Online · 2010 · 4.4K citations